| Sotorasib for Lung Cancers with KRAS p.G12C Mutation F Skoulidis, BT Li, GK Dy, TJ Price, GS Falchook, J Wolf, A Italiano, ... New England Journal of Medicine 384 (25), 2371-2381, 2021 | 1464 | 2021 |
| Artificial intelligence in digital pathology—new tools for diagnosis and precision oncology K Bera, KA Schalper, DL Rimm, V Velcheti, A Madabhushi Nature reviews Clinical oncology 16 (11), 703-715, 2019 | 1307 | 2019 |
| Programmed death ligand-1 expression in non-small cell lung cancer V Velcheti, KA Schalper, DE Carvajal, VK Anagnostou, KN Syrigos, ... Laboratory investigation 94 (1), 107-116, 2014 | 942 | 2014 |
| Quantitative assessment of the heterogeneity of PD-L1 expression in non–small-cell lung cancer J McLaughlin, G Han, KA Schalper, D Carvajal-Hausdorf, V Pelekanou, ... JAMA oncology 2 (1), 46-54, 2016 | 884 | 2016 |
| Efficacy of Selpercatinib in RET Fusion–Positive Non–Small-Cell Lung Cancer A Drilon, GR Oxnard, DSW Tan, HHF Loong, M Johnson, J Gainor, ... New England Journal of Medicine 383 (9), 813-824, 2020 | 789 | 2020 |
| In Situ Tumor PD-L1 mRNA Expression Is Associated with Increased TILs and Better Outcome in Breast Carcinomas KA Schalper, V Velcheti, D Carvajal, H Wimberly, J Brown, L Pusztai, ... Clinical cancer research 20 (10), 2773-2782, 2014 | 548 | 2014 |
| Predicting cancer outcomes with radiomics and artificial intelligence in radiology K Bera, N Braman, A Gupta, V Velcheti, A Madabhushi Nature reviews Clinical oncology 19 (2), 132-146, 2022 | 483 | 2022 |
| Radiomics and radiogenomics in lung cancer: a review for the clinician R Thawani, M McLane, N Beig, S Ghose, P Prasanna, V Velcheti, ... Lung cancer 115, 34-41, 2018 | 480 | 2018 |
| Incidence of pneumonitis with use of programmed death 1 and programmed death-ligand 1 inhibitors in non-small cell lung cancer: a systematic review and meta-analysis of trials M Khunger, S Rakshit, V Pasupuleti, AV Hernandez, P Mazzone, ... Chest 152 (2), 271-281, 2017 | 464 | 2017 |
| Objective measurement and clinical significance of TILs in non–small cell lung cancer KA Schalper, J Brown, D Carvajal-Hausdorf, J McLaughlin, V Velcheti, ... Journal of the National Cancer Institute 107 (3), dju435, 2015 | 432 | 2015 |
| Selective RET kinase inhibition for patients with RET-altered cancers V Subbiah, V Velcheti, BB Tuch, K Ebata, NL Busaidy, ME Cabanillas, ... Annals of Oncology 29 (8), 1869-1876, 2018 | 405 | 2018 |
| ALT-803, an IL-15 superagonist, in combination with nivolumab in patients with metastatic non-small cell lung cancer: a non-randomised, open-label, phase 1b trial JM Wrangle, V Velcheti, MR Patel, E Garrett-Mayer, EG Hill, JG Ravenel, ... The Lancet Oncology 19 (5), 694-704, 2018 | 401 | 2018 |
| Targeting RET in Patients With RET-Rearranged Lung Cancers: Results From the Global, Multicenter RET Registry O Gautschi, J Milia, T Filleron, J Wolf, DP Carbone, D Owen, R Camidge, ... Journal of Clinical Oncology 35 (13), 1403-1410, 2017 | 373 | 2017 |
| Perinodular and intranodular radiomic features on lung CT images distinguish adenocarcinomas from granulomas N Beig, M Khorrami, M Alilou, P Prasanna, N Braman, M Orooji, S Rakshit, ... Radiology 290 (3), 783-792, 2019 | 314 | 2019 |
| The current state of the art and future trends in RAS-targeted cancer therapies SR Punekar, V Velcheti, BG Neel, KK Wong Nature reviews Clinical oncology 19 (10), 637-655, 2022 | 307 | 2022 |
| Expression analysis and significance of PD-1, LAG-3, and TIM-3 in human non–small cell lung cancer using spatially resolved and multiparametric single-cell analysis I Datar, MF Sanmamed, J Wang, BS Henick, J Choi, T Badri, W Dong, ... Clinical Cancer Research 25 (15), 4663-4673, 2019 | 299 | 2019 |
| Changes in CT radiomic features associated with lymphocyte distribution predict overall survival and response to immunotherapy in non–small cell lung cancer M Khorrami, P Prasanna, A Gupta, P Patil, PD Velu, R Thawani, ... Cancer immunology research 8 (1), 108-119, 2020 | 259 | 2020 |
| Spatial architecture and arrangement of tumor-infiltrating lymphocytes for predicting likelihood of recurrence in early-stage non–small cell lung cancer G Corredor, X Wang, Y Zhou, C Lu, P Fu, K Syrigos, DL Rimm, M Yang, ... Clinical cancer research 25 (5), 1526-1534, 2019 | 259 | 2019 |
| State-of-the-Art Strategies for Targeting RET-Dependent Cancers V Subbiah, D Yang, V Velcheti, A Drilon, F Meric-Bernstam Journal of Clinical Oncology 38 (11), 1209-1221, 2020 | 234 | 2020 |
| Rational design of anti-GITR-based combination immunotherapy R Zappasodi, C Sirard, Y Li, S Budhu, M Abu-Akeel, C Liu, X Yang, ... Nature Medicine 25 (5), 759-766, 2019 | 234 | 2019 |
Anant MadabhushiDepartment of Biomedical Engineering, Professor, Biomedical Engineering, Emory Univ & Georgia TechZweryfikowany adres z emory.edu